LadRx Corp (LADX) Stock Price, Trades & News

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	6.33
	9-Day RSI	18.35
	14-Day RSI	26.63
	3-1 Month Momentum %	109.8
	6-1 Month Momentum %	872.73
	12-1 Month Momentum %	-93.33

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History

Financials (Next Earnings Date:2026-07-14 Est.)

Annual Quarterly TTM

LADX's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:LADX

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

LadRx Corp Executives

Details

GF Value™

LADX

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with LADX. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)
	EPS (TTM) ($)	-5.04
	Beta	0.7239
	3-Year Sharpe Ratio	0.45
	3-Year Sortino Ratio	2.08
	Volatility %	887.5
	14-Day RSI	26.63
	14-Day ATR ($)	0.00607
	20-Day SMA ($)	0.059
	12-1 Month Momentum %	-93.33
	52-Week Range ($)	0.0001 - 2.2
	Shares Outstanding (Mil)	0.5

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

LadRx Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

LadRx Corp Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-16	In 132 days
Second quarter earnings results for 2026	2026-08-20	In 44 days
First quarter earnings results for 2026	2026-07-14	In 7 days
Annual report for 2025	2026-07-07	0.01 (+0.00%)
General meeting for 2025	2026-07-07	0.01 (+0.00%)
First quarter earnings results for 2025	2025-05-14	1.68 (+0.00%)
Annual report for 2024	2025-03-28	1.49 (-0.67%)
Virtual Life Science Investor Forum	2025-03-13 15:00	1.89 (+0.00%)
Third quarter earnings results for 2024	2024-11-14	1.18 (-0.30%)
General meeting for 2024	2024-10-04 10:00	1.80 (+0.00%)

Show

Entries

LadRx Corp Frequently Asked Questions

What is LadRx Corp(LADX)'s stock price today?

The current price of LADX is $0.01. The 52 week high of LADX is $2.20 and 52 week low is $0.00.

When is next earnings date of LadRx Corp(LADX)?

The next earnings date of LadRx Corp(LADX) is 2026-07-14 Est..

Does LadRx Corp(LADX) pay dividends? If so, how much?

LadRx Corp(LADX) does not pay dividend.

Guru Commentaries on OTCPK:LADX

No articles.

Press Release

	Subject	Date
	CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders	2020-08-10
	CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C	2020-07-21
	CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease	2020-06-29
	CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease	2020-04-29
	CytRx Corporation Provides Update on Management Change	2020-03-10
	CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin	2020-01-29
	CytRx Corporation Reports Second Quarter 2019 Financial Results	2019-08-09
	CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis	2019-07-22
	CytRx Corporation to Commence Trading on OTCQB Venture Market	2019-05-31
	CytRx Corporation Reports First Quarter 2019 Financial Results	2019-05-15

10/Page

Articles on LadRx Corp

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.